Filing Details

Accession Number:
0001439222-24-000052
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-03-05 16:18:08
Reporting Period:
2024-03-01
Accepted Time:
2024-03-05 16:18:08
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1439222 Agios Pharmaceuticals Inc. AGIO Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1840056 Cecilia Jones C/O Agios Pharmaceuticals, Inc.
88 Sidney Street
Cambridge MA 02139
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-03-01 2,000 $0.00 15,512 No 4 M Direct
Common Stock Disposition 2024-03-05 672 $32.57 14,840 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted stock units Acquisiton 2024-03-01 17,000 $0.00 17,000 $0.00
Common Stock Stock options (right to buy) Acquisiton 2024-03-01 60,000 $0.00 60,000 $32.27
Common Stock Restricted stock units Disposition 2024-03-01 2,000 $0.00 2,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
17,000 No 4 A Direct
60,000 2034-03-01 No 4 A Direct
4,000 No 4 M Direct
Footnotes
  1. Includes 942 shares purchased through the Company's employee stock purchase plan.
  2. Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023.
  3. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
  4. The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments.
  5. This option was granted on March 1, 2024. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2025, with the remaining 75% vesting in 36 equal monthly installments thereafter.
  6. The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments.